Compare Hims and Hers Health Inc (HIMS) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Nasdaq Inc — how do they compare? Hims and Hers Health Inc trades at $29.32 (market cap $6.55B), while Nasdaq Inc trades at $93.54 (market cap $51.63B). The key difference: Nasdaq Inc is far larger — about 7.9× Hims and Hers Health Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Nasdaq Inc for 125 Days on average.
| HIMS | NDAQ | |
|---|---|---|
Market Cap | $6.55B | $51.63B |
Volume | 14,842,814 | 2,668,175 |
Sector | Health | Financials |
52-Week High | $62.76 | $100.98 |
52-Week Low | $14.52 | $76.85 |
Typical Hold Time | 21 Days | 125 Days |
Enterprise Value | $7.25B | $58.09B |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Nasdaq (NDAQ) trades at $93.51, up 1.72% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. Analyst consensus is a Buy with a $110.43 price target, supported by positive news on AI platform adoption and index changes.
Outlook remains positive given earnings momentum and Financial Technology growth, though risks include market volatility and debt levels. The stock offers upside to consensus targets but faces execution risks in tech integration and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
